BIAF 0.97 (-10.19%)
US09076W1099Medical Diagnostics & ResearchDiagnostics & Research

BioAffinity Technologies (BIAF) Competitor Comparison

We are evaluating the key criteria listed to compare BioAffinity Technologies (BIAF) against its competitors in the Diagnostics & Research industry.

Linearity 10 years - BIAF ranking 31 / 58

These are the competitors of BioAffinity Technologies in the industry Diagnostics & Research ranked by linearity 10 years
1. Ortho Clinical Diagnostics Holdings OCDX
33.4
2. Guardant Health GH
25.94
3. Anixa Biosciences ANIX
14.9
4. Illumina ILMN
13.46
5. National Research NRC
12.91
6. Neogen NEOG
12.56
7. Olink Holding OLK
8.11
8. Inotiv NOTV
6.92
9. Global Cord Blood CO
5.67
10. DarioHealth DRIO
4.86
11. Pacific Biosciences of California PACB
4.7
12. Fulgent Genetics FLGT
4.61
13. Sera Prognostics SERA
3.91
14. Myriad Genetics MYGN
3.86
15. Syneos Health SYNH
3.71
16. Sotera Health SHC
3.63
17. Bioventus BVS
3.25
18. Co-Diagnostics CODX
3.21
19. Enzo Biochem ENZ
3.08
20. Qiagen QGEN
2.95
21. Psychemedics PMD
2.8
22. Exagen XGN
2.69
23. Exact Sciences EXAS
2.56
24. Aspira Womens Health AWH
2.28
25. Meridian Bioscience VIVO
2.1
26. MDxHealth MDXH
2.09
27. MaxCyte MXCT
2.02
28. Personalis PSNL
1.95
29. Twist Bioscience TWST
1.93
30. Biodesix BDSX
1.92
31. bioAffinity Technologies BIAF
1.84
32. Prenetics Global PRE
1.8
33. NeoGenomics NEO
1.79
34. CareDx CDNA
1.69
35. Organovo Holdings ONVO
1.66
36. Charles River Laboratories CRL
1.65
37. Neuronetics STIM
1.62
38. Trinity Biotech TRIB
1.57
39. SeqLL SQL
1.42
40. Quest Diagnostics DGX
1.37
41. Interpace Biosciences IDXG
1.33
42. Laboratory Corp of America Holdings LH
1.26
43. PerkinElmer PKI
1.15
44. IQVIA Holdings IQV
1.09
45. Precipio PRPO
1.04
46. Icon ICLR
1
47. DexCom DXCM
1
48. Agilent Technologies A
0.82
49. Mettler-Toledo MTD
0.8
50. Danaher DHR
0.75
51. Thermo Fisher Scientific TMO
0.73
52. Waters WAT
0.71
53. IDEXX Laboratories IDXX
0.71
54. Heska HSKA
0.52
55. RadNet RDNT
0.47
56. Natera NTRA
0.46
57. Lantheus Holdings LNTH
0.33
58. Medpace Holdings MEDP
0.23

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.